Janssen Boosts Multiple Myeloma R&D With Genmab Deal
This article was originally published in The Pink Sheet Daily
Executive Summary
Janssen Biotech has signed its second deal in less than two months with antibody discovery company Genmab, this time licensing the Danish company's potential first-in-class multiple myeloma therapy daratumumab for $55 million upfront and an equity investment.